Efpeglenatide
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Efpeglenatide is a GLP-1 receptor agonist under development for the treatment of type 2 diabetes and obesity and reducing the risk of cardiovascular incidents in people with these conditions.[1][2][3][4][5][6][7] Its developer is Hanmi Pharmaceutical.[8]
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEMBL | |
